Evidence map›Paper›PMID 31975908›Full record

ReviewFocus (American Psychiatric Publishing)2018

Biomarkers in Autism Spectrum Disorder: Challenges, Advances, and the Need for Biomarkers of Relevance to Public Health.

Ami Klin

Open access · greenAbstract readReview
In one paragraph

Review in Focus (American Psychiatric Publishing), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Diversity of words and words for diversity.Frontiers in psychiatry · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Isolation and Characterization of Cell-Free DNA from Cerebral Organoids.International journal of molecular sciences · 2024
    Article
  11. Article
  12. Article
  13. Higher Levels of Galectin-1 and Galectin-3 in Young Subjects with Autism Spectrum Disorder Compared to Unaffected Siblings and Healthy Controls.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2023
    Article
  14. Article
  15. Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Biomarkers: Where Are We Going?Focus (American Psychiatric Publishing) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ami KlinDr. Klin is with the Division of Autism & Related Disabilities, Department of Pediatrics, Emory University School of Medicine, Atlanta, George, and the Marcus Autism Center, Children's Healthcare of Atlanta.
Center for Autism and Related Disorders · US

Funding

The ontogeny of social vocal engagement and its derailment in autismP50MH100029 · NIMH · EMORY UNIVERSITY · PI RAMSAY, GORDON JAMES · 2012 to 2021
$20.1M
Early Quantitative Characterization of Reciprocal Social BehaviorR01HD068479 · NICHD · WASHINGTON UNIVERSITY · PI CONSTANTINO, JOHN N. · 2012 to 2016
$2.7M
The Ontogeny of Social Visual Engagement in Infants at Risk for AutismR01MH083727 · NIMH · YALE UNIVERSITY · PI JONES, WARREN · 2008 to 2012
$2.7M
NICHD NIH HHS R01 HD068479NIMH NIH HHS P50 MH100029NIMH NIH HHS R01 MH083727
6 · The paper itself

Abstract

Although autism spectrum disorder (ASD) is the most strongly genetic of all complex neuropsychiatric disorders, it is still defined and diagnosed behaviorally. The vast genotypic and phenotypic heterogeneity of the condition necessitate a vigorous search for biological markers capable of aiding in diagnosis, identifying more homogeneous subgroups for biological study, individualizing treatment, and measuring treatment response. Many candidate biomarkers are available, spanning genetic, metabolic, electroencephalographic, magnetic resonance imaging, and neuropsychological methods. Although biomarker research has focused primarily on mechanistic etiologic hypotheses, the biomarkers more likely to result in optimized clinical outcomes in the near term are cost-effective and community-viable measures obtained through eye-tracking technology involving infants and toddlers. Although these tools are still far from being ready for widespread application, the goal is to develop objective procedures and measures for population-based screening and diagnosis to increase access to early treatment and intervention.

Indexed as

Autismbiomarkers

Identifiers

PMID31975908
PMCPMC6526849
OpenAlexW2802507752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.